pharmaphorum2d
UCB looks ahead to next phase
the company's current head of Biopharma Brands and Solutions, to be its new leader from 2015. "UCB has three promising products in phase III: brivaracetam for epilepsy, lupus treatment epratuzumab ...
UCB SA (0NZT) Receives a Buy from Barclays
In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...
ENDPOINTS NEWS9d
Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess
Biogen and UCB on Tuesday shared an expanded dataset for their Phase 3 lupus program, which they said two months ago ...
Crohn’s Disease Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Pipeline, Epidemiology and Companies by DelveInsight
DelveInsight's "Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth ...
BioWorld8d
UCB chalks hidradenitis suppurativa as fifth indication for Bimzelx
The U.S. FDA added hidradenitis suppurativa to the label for UCB SA’s Bimzelx (bimekizumab-bkzx), throwing renewed light on the indication, a chronic disease that causes painful, boil-like lumps that ...
pharmaphorum3d
UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trial
Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.
Business Insider4mon
Barclays Remains a Buy on UCB SA (0NZT)
Begin your TipRanks Premium journey today. UCB SA (0NZT) Company Description: UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous ...